Insulet (PODD): AQR CAPITAL MANAGEMENT LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
AQR Capital Management disclosed a stake exceeding 5% in Insulet (PODD) via a Schedule 13G filing with the SEC (accession 0001167557-26-000278). The filing signals the quantitative asset manager has crossed the 5% beneficial ownership threshold that triggers passive-investor disclosure requirements. Insulet, maker of the Omnipod insulin delivery system, now counts AQR among its largest institutional holders. The exact share count and percentage were not specified in the headline disclosure. Investors will watch for further 13G amendments or 13D filings to gauge whether AQR's position is passive or activist in nature.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
AQR Capital Management LLC, Insulet (PODD)
A linked name opens that asset's sentiment page.